Enzymlogic is a world leader in the kinetic profiling of compounds to facilitate drug discovery. As experts in the generation and interpretation of kinetic data, we pride ourselves on a proven track record of successful partnerships with worldwide organizations of all sizes, supporting them on a routine basis during the early phases of drug discovery. We focus on the Hit to Lead (H2L) and Lead Optimization (LO) stages of drug discovery where our optimized kinetic profiling assays identify compounds with therapeutic potential that merit further progression into clinical trials. Our expertise in protein science and high-throughput screening enables drug hunters to speed up discovery decision-making, choosing the most promising molecules and eliminating under-performers, through a deeper understanding of the kinetics of compound-target interactions. We use exquisitely tuned assays to deliver accurate, robust and reproducible kinetic data of the highest quality that enhances the identification of compounds with the greatest therapeutic potential. The insight we provide facilitates the screening of compounds to iterate medicinal chemistry, understand pharmacokinetics/pharmacodynamics (PK/PD) disconnects and build better models to define therapeutic windows. You can email at info@enzymlogic.com to request further information on Enzymlogic’s drug discovery services and partnering information.